8-K Announcements
6Material company update
May 5, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Apr 2, 2026·SEC
Azenta, Inc.(AZTA)Earnings, Financials & Key Ratios
AZTA•NASDAQ
$25.37
Price updated Jul 7, 2026
AboutAzenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.Show more
- Revenue$594M+3.6%
- EBITDA$50M-17.8%
- Net Income-$56M+66.2%
- EPS (Diluted)-1.22+60.5%
- Gross Margin45.52%+2.5%
- EBITDA Margin8.41%-20.6%
- Operating Margin-1.9%+63.7%
- Net Margin-9.39%+67.3%
- ROE-3.19%+58.4%
AZTA Price & Volume
Azenta, Inc. (AZTA) stock price & volume — 10-year historical chart
Loading chart...
Stagnant Revenue Growth Challenges Operational Margin Recovery
Investment Thesis • Updated 2026Q2
VerdictNeutral
Growth:Mixed
Profitability:Negative
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Biotech R&D spending volatility
Key Thesis Takeaways
- Azenta faces a difficult transition period characterized by stagnant top-line growth of 1.0% in 2026Q2 and persistent operating losses, which suggest that its high-cost laboratory infrastructure is not yet scaling effectively.
- While the company maintains a robust balance sheet with a conservative 0.04 debt-to-equity ratio, the reliance on past acquisitions—evidenced by $552.4 million in goodwill—creates significant valuation risk.
- Investors should monitor whether the company can achieve consistent positive operating margins above its recent -10.6% level before committing capital to this volatile biotech-exposed service provider.
Verdict Logic
while the company holds a strong liquidity buffer with a 2.83 current ratio, the lack of consistent profitability and the -10.6% operating margin suggest that the business model requires further validation before a long-term investment case can be supported.
AZTA Growth Metrics
Azenta, Inc. (AZTA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years0.72%
5 Years8.85%
3 Years2.25%
TTM1.85%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-175.49%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-184.89%
Return on Capital
10 Years0.84%
5 Years-1.06%
3 Years-1.53%
Last Year-0.61%
AZTA Recent Earnings
Azenta, Inc. (AZTA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$0.04-140.0%
$0.10
Rev
$145M-2.4%
$148M
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$0.09-18.2%
$0.11
Rev
$149M+1.1%
$147M
Q4 2025
Nov 21, 2025Metric
Actual
Est
EPS
$0.21+10.8%
$0.19
Rev
$159M+1.9%
$156M
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.19+46.2%
$0.13
Rev
$144M-8.1%
$157M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $0.04vs $0.10-140.0% | $145Mvs $148M-2.4% |
| Q1 2026 | Feb 4, 2026 | $0.09vs $0.11-18.2% | $149Mvs $147M+1.1% |
| Q4 2025 | Nov 21, 2025 | $0.21vs $0.19+10.8% | $159Mvs $156M+1.9% |
| Q3 2025 | Aug 5, 2025 | $0.19vs $0.13+46.2% | $144Mvs $157M-8.1% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Azenta, Inc. (AZTA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.37 | $1.17B | -20.80 | 3.55% | -9.39% | -3.19% | — | |
| $96.20 | $11.65B | -155.16 | 24.12% | -10.93% | -7.04% | — | |
| $27.93 | $1.36B | -111.72 | 16.97% | -10.52% | -2.91% | — | |
| $55.08 | $1.1B | 18.86 | 6.77% | 16.03% | 27.71% | — | |
| $36.67 | $674.65M | 8.43 | -0.2% | 25.09% | 5285.71% | — | |
| $38.72 | $7.99B | 18.98 | 5.65% | 19.16% | 11.28% | — |
Compare AZTA vs Peers
Azenta, Inc. (AZTA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AZTA SEC Filings & Documents
Azenta, Inc. (AZTA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AZTA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AZTA Frequently Asked Questions
Azenta, Inc. (AZTA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Azenta, Inc.'s revenue?
Azenta, Inc. (AZTA) reported $596.6M in revenue for fiscal year 2025. This represents a 560% increase from $90.4M in 1996.
How fast is Azenta, Inc. growing?
Azenta, Inc. (AZTA) grew revenue by 3.6% over the past year. Growth has been modest.
Is AZTA profitable?
Azenta, Inc. (AZTA) reported a net loss of $178.2M for fiscal year 2025.
Dividend & Returns
What is AZTA's return on equity?
Azenta, Inc. (AZTA) has a return on equity (ROE) of -3.2%. Negative ROE indicates the company is unprofitable.
What is Azenta, Inc.'s free cash flow?
Azenta, Inc. (AZTA) generated $28.7M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.